The World Organisation for Animal Health (WOAH) has published the first report of its Ad Hoc Group on the Prioritisation of Diseases for which Vaccines Could Reduce Global Antimicrobial Use in Animals (PROEVA), identifying key diseases where improved vaccination strategies could have the greatest impact on reducing antimicrobial use (AMU) worldwide.
The initiative responds directly to Commitment #72 of the 79th United Nations General Assembly Political Declaration on Antimicrobial Resistance (AMR), which calls on countries to ensure that animal vaccination strategies are in place by 2030, taking into account WOAH’s priority disease lists for which vaccines can reduce antimicrobial use.
WOAH previously developed global priority disease lists in 2015 and 2018. However, changing disease patterns, climate-related pressures, advances in vaccine technology, and growing political commitments to combat AMR prompted the need for an updated assessment. To address this, WOAH convened a multidisciplinary group of experts from academia, regulatory authorities, animal production sectors, and vaccine research and manufacturing.
The group has now updated the priority disease lists for pigs, poultry, and fish and identified a “Top 6” list of diseases where vaccination could contribute most significantly to reducing antimicrobial use globally:
Pigs
- Porcine Reproductive and Respiratory Syndrome (PRRS) virus
- Escherichia coli
Poultry
- Eimeria species
- Escherichia coli
Fish
- Freshwater cichlids: Streptococcus iniae and Streptococcus agalactiae
- Freshwater cyprinids: Aeromonas hydrophila and other Aeromonas species
These diseases were selected based on their impact on animal health, their contribution to antimicrobial use, and the potential for vaccination to reduce the need for treatment.
Vaccination is recognised by WOAH as one of the most effective tools for preventing infectious diseases and reducing reliance on antimicrobials.
“By identifying priority diseases, WOAH aims to help direct investment and innovation towards vaccines that can have the greatest impact on reducing antimicrobial use and supporting sustainable production systems,” Dr. Flavie Vial, Programme Officer on Vaccines and Vaccination, stated.
The next phase of the PROEVA initiative will focus on developing Target Product Profiles (TPPs) for the priority pathogens. These profiles will help guide vaccine research, development, regulatory planning, and investment by defining the characteristics needed for future vaccines to maximise their impact on reducing antimicrobial use.
The updated priority disease lists are expected to support governments, researchers, funders, and industry stakeholders in aligning efforts towards the global goal of reducing antimicrobial use and tackling antimicrobial resistance by 2030.